Two drugs that account for more than half of Gilead Sciences, Inc.’s (NASDAQ: GILD) sales may also cause abnormally slow heartbeats, according to a warning sent by the company on Friday.
Shares of Gilead were lower by more than 3 percent in pre-market trading.
According to the warning, two of Gilead’s Hepatitis C drugs, Sovaldi and Harvoni, may have adverse reactions when mixed with amiodarone, a drug that treats heart rhythm problems.
Harvoni’s $2.1 billion and Sovaldi’s $1.73 billion account for more than half of the company’s total $7.31 billion in revenues.
Baird analysts shrugged off the label changes in a note out Monday, saying that the label changes are “not meaningful.” In fact, the analysts recommended that investors use “near-term stock weakness as a buying opportunity.” The analysts pegged the adverse drug reaction rate at less than 1 percent of treated patients.
Baird reiterated its price target of $126.
Gilead has gained more than 40 percent over the past year, as the biotech sector has outperformed the broader market.
Shares closed Friday at $102.29, but were below $100 in pre-market trading.
Latest Ratings for GILD